close
The Wayback Machine - https://web.archive.org/web/20210505035148/https://www.owler.com/company/biogen
Search companies on Owler
Advanced Search
Latest news
Newsfeed
My followed companies
Followed Companies

Biogen

Biogen develops, manufactures and markets therapies for patients living with serious neurological, autoimmune and hematologic disorders. Read more

11,682 Followers on Owler
11,682 Followers on Owler
11,682 Followers on Owler
11,682 Followers on Owler

Biogen

Biogen develops, manufactures and markets therapies for patients living with serious neurological, autoimmune and hematologic disorders. Read more

Michel Vounatsos's photo - CEO of Biogen

CEO

Michel Vounatsos

CEO Approval Rating

49/100

Founded:

1978

Status:

PublicIndependent CompanyNASDAQBIIB

SIC Code:

2836 NAICS listing »

Website:

Annual Revenue
Employees
Sector
Biotechnology
Headquarters

BIOGEN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

The top 10 competitors in Biogen's competitive set are Sanofi, Bayer, TEVA, Novartis, Genentech, EMD Serono, Roche, Amgen, Pfizer, GSK. Together they have raised over 38.7B between their estimated 1.3M employees. Biogen has 7,800 employees and is ranked 20th among it's top 10 competitors. The top 10 competitors average 47,450.

Sanofi is perceived as one of Biogen's biggest rivals. Sanofi's headquarters is in Paris, Île-de-France, and was founded in 1994. Sanofi operates in the Pharmaceuticals industry. Sanofi generates 330% of Biogen's revenue.

Bayer has been one of Biogen's top competitors. Bayer is a Public company that was founded in 1863 in Leverkusen, North Rhine-Westphalia. Bayer is in the Medical Research & Laboratories field. Compared to Biogen, Bayer has 91,738 more employees.

TEVA is Biogen's #3 rival. TEVA was founded in Petach Tikva, Center District} in 1901. TEVA operates in the Pharmaceuticals industry. Compared to Biogen, TEVA generates $2.9B more revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is EMD Serono a competitor of Biogen?

I don't know

Trending News for Biogen and Biogen's Competitors

May 4, 2021

Pharmafile

Novartis eye treatment for diabetics shows positive results in Phase III trial

Novartis' Beovu treatment for diabetic macular edema (DME) - an eye condition that can cause blindnes... See more »

May 4, 2021

The Journal Record

EU drug regulator evaluating Pfizer vaccine for youngsters

The European Union's drug regulator said Monday it has begun evaluating a request by Pfizer Inc. and ... See more »

May 3, 2021

Law 360

Sanofi Misled Buyers About Pain Relief Patches, Suit Says

A proposed class of consumers accused Sanofi US Corp. of misrepresenting the strength and longevity o... See more »

Biogen Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$13.4B

Biogen's revenue is the ranked 17th among it's top 10 competitors. The top 10 competitors average 24.9B. Over the last four quarters, Biogen's revenue has decreased by 19.3%. Specifically, in Q4 2020's revenue was $2.9B; in Q3 2020, it was $3.4B; in Q2 2020, it was $3.7B; in Q1 2020, Biogen's revenue was $3.5B.

Biogen Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Nightstar Therapeutics Plc

Mar 2019

Source »
$800M
Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

These are all the companies that Biogen has acquired. Biogen's latest acquisition was Nightstar Therapeutics Plc in Mar 2019. Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

Biogen Funding History

No recent funding data found related to Biogen

Biogen Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Autobahn Therapeutics develops and commercializes regenerative medicines for the treatment of central nervous system disorders.
$76M
Jun 08, 2020
Series B
-
Samsung Bioepis develops and produces biopharmaceutical and biosimilar products.
$673.4M
Jul 28, 2018
Equity
-
Solid Biosciences develops and commercializes gene therapies for the treatment of Duchenne muscular dystrophy disorder.
$50M
Mar 29, 2017
Series C
Jan 25, 2018
Yumanity Therapeutics develops and commercializes drug-based therapies for the treatment of neurodegenerative diseases.
$51M
Feb 07, 2016
Series A
-
Rodin is a biotechnology company that discovers, develops and commercializes therapeutics for the treatment of neurologic diseases.
$17.3M
Jan 05, 2016
Equity
Nov 01, 2019

These are all the companies that Biogen has invested in. Biogen's latest investment was Nightstar Therapeutics Plc in Mar 2019. Nightstar develops novel therapies for the treatment of rare inherited retinal diseases.

Biogen News

April 28, 2021Markets Insider

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that ... See more »
April 27, 2021The Business Journals

After pressure, Biogen to expand compassionate use for ALS drug

Following pressure by advocates for patients with amyotrophic lateral sclerosis, or ALS, Biogen has e... See more »
April 27, 2021Endpoints News

Biogen's Michel Vounatsos takes home $18.7M in pay as the company battles to take aducanumab to market

Biogen found itself at the center of controversy late last year as it worked with the FDA to grease t... See more »
April 26, 2021The Business Journals: Boston

Biogen CEO nets highest-ever pay for second year in a row

For the second year in a row, Biogen CEO Michel Vounatsos has nabbed his highest-ever compensation, e... See more »
April 23, 2021Pharmaceutical Processing World

Biogen Q1 earnings beat estimates, raises EPS guidance

Biogen (NASDAQ: BIIB) posted first-quarter results that beat the Wall Street consensus forecast, with... See more »
April 22, 2021The Pharma Letter

Biogen beats expectations, despite 24% sales dive

US biotech major Biogen today reported first quarter 2021 financial results which, though well below.... See more »
April 22, 2021Benzinga

Biogen's Shares Are Trading Lower On 71% Quarterly Profit Slump, Weak Tecfidera Sales

Biogen Inc (NASDAQ: BIIB) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis dr... See more »

Biogen Press Releases

January 11, 2021NewsFile

January 12, 2021

New York, New York--(Newsfile Corp. - January 11, 2021) - Bronstein, Gewirtz & Grossman, LLC notifies... See more »
December 17, 2020StreetInsider

Pharma Giant And Speciality Pharmacy Settle Case Alleging False Claims Violations

BOSTON, Dec. 17, 2020 /PRNewswire/ -- One of the world's largest pharmaceutical companies, Biogen, In... See more »
December 16, 2020centralcharts

ROSEN, RESPECTED INVESTOR COUNSEL, Reminds Biogen Inc. Investors of Important January 12 Deadline in First Filed Securities Class Action Commenced by the Firm; Encourages Investors with Losses in Excess of $1 Million to Contact the Firm - BIIB

See more »
December 16, 2020NewsFile

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

New York, New York--(Newsfile Corp. - December 16, 2020) - Pomerantz LLP is investigating claims on b... See more »
December 8, 2020GlobalNewswire

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of invest... See more »
December 4, 2020Business Wire

December 7, 2020

NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action ... See more »
December 4, 2020CSRwire

New Coalition Aims To Close The Opportunity Gap In Bioscience

Liftstream, New England Venture Capital Association (NEVCA), Third Rock Ventures, Biogen Inc. (NASDAQ... See more »

Biogen Videos

March 9, 2021Biogen Youtube Channel

"MS Beyond Words - Donna's story (Punjabi)" on YOUTUBE

See more »
March 2, 2021Biogen Youtube Channel

"Cleo - die App, die dir hilft, deinen Alltag mit MS zu meistern" on YOUTUBE

See more »
February 24, 2021Biogen Youtube Channel

"O raro tambm pode acontecer - Marco motor de ficar em p com apoio" on YOUTUBE

See more »
February 23, 2021Biogen Youtube Channel

"Leben mit MS - Ernhrungstipps Teil 3" on YOUTUBE

See more »
February 23, 2021Biogen Youtube Channel

"MSbeyondwords - Samira's Geschichte" on YOUTUBE

See more »
February 23, 2021Biogen Youtube Channel

"MSbeyondwords - Donna's Geschichte" on YOUTUBE

See more »
February 23, 2021Biogen Youtube Channel

"MSbeyondwords - Daniel's Geschichte" on YOUTUBE

See more »

Social Media

Biogen Headquarters

225 Binney Street

Cambridge, Massachusetts02142

781-464-2000

Driving Directions »

Trending Companies

Biogen Summary

ABOUT

Overview

Biogen develops, manufactures and markets therapies for patients living with serious neurological, autoimmune and hematologic disorders. Biogen was founded in 1978. Biogen's headquarters is located in Cambridge, Massachusetts, USA 02142. Biogen's late...

CEO

Biogen's CEO, Michel Vounatsos, currently has an approval rating of 49%. Biogen's primary competitors are Sanofi, Bayer & TEVA.

Website

biogen.com

Frequently Asked Questions about Biogen

  1. When was Biogen founded?

    Biogen was founded in 1978

  2. Who is Biogen's CEO?

    Biogen's CEO is Michel Vounatsos

  3. How much revenue does Biogen generate?

    Biogen generates $13.4B in revenue

  4. How much funding does Biogen have?

    Biogen has historically raised $0 in funding

  5. Where is Biogen's headquarters?

    Biogen's headquarters is in Cambridge Massachusetts, USA

  1. How many employees does Biogen have?

    Biogen has 7,800 employees

  2. What sector does Biogen operate in?

    Biogen is in Biotechnology

  3. Who are Biogen's competitors?

    Biogen's top competitors are Sanofi, Bayer, TEVA

  4. Who has Biogen invested in?

    Biogen's has invested in companies such as Autobahn, Samsung Bioepis, Solid Biosciences
Stay up-to-date with the latest news on Biogen

© 2021 Owler, Inc.